• Track And Trace In The Drug Supply Chain
    Track And Trace In The Drug Supply Chain

    Though the timelines may vary, across the globe more and more countries are requiring product identifiers and serialization of prescription drugs — right down to individual salable units. As global guidelines take full effect, it is worth understanding how contract manufacturing organizations are preparing themselves to comply to meet the needs of their customers.

  • What Dosage Form Provides A Release Drug Control Rate?

    Whether your goal is to increase patient compliance, improve clinical outcomes, or to extend a product’s lifecycle, modified-release dosage forms present a solution to myriad challenges. The trick is to understand the influence of both drug property and delivery technology on drug design, and to give you enough time to select and introduce the ideal release form for both therapeutic and economic advantage.

  • Is Your CMO Ready For Serialization And Aggregation?

    While some are waiting for mandates for traceability, serialization, and aggregation, others are recognizing the inevitability of these strategies. Does your CMO have a dedicated traceability operation within the company and serialization efforts in place?

  • Avoiding HPAPI Contamination

    Strict regulations regarding the manufacture of HPAPIs require that pharmaceutical companies and contract manufacturing organizations (CMO) carefully select equipment, outline processes and deploy appropriate containment strategies. Read how partnering with a knowledgeable and experienced CMO for this important stage of a drug’s life cycle can reduces costs and timelines, and ensures the safety of employees, the environment and the patient.

  • End-To-End Process For Oncolytic Adenovirus Production

    Oncolytic viruses constitute a new promising therapeutic approach for treatment of cancer. Here’s an example of a scalable, end-to-end process for oncolytic adenovirus production using modern tools and technologies.

  • Putting The “Process” Into Process Characterization

    Done correctly, Process Characterization reduces the risk of manufacturing failures and regulatory delays. Scientists at the AbbVie Bioresearch Center (ABC) have established a platform approach to Process Characterization that has been proven effective as it has been used to support the approval of several marketed products.

More Insights On Enterprise Solutions


  • Standing Out In The Crowded Biopharmaceutical Contract Manufacturing Market
    Standing Out In The Crowded Biopharmaceutical Contract Manufacturing Market

    Differentiating one’s CDMO offering from competitors is an essential component of gaining awareness, familiarity, and being awarded business. When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offering to the right audience at the right time. 

  • Singota Solutions—Focused on Faster

    This video introduces Singota Solutions, a CDMO focused on getting products to patients faster by being agile, accountable and transparent. A team of industry experts help virtual to large pharma clients reach preclinical and clinical milestones faster with shorter lead times and agile onsite operations. Services in formulation development, finishing and supply chain support Singota’s flagship aseptic filling operations. A gloveless robotic isolator provides highly repeatable and precise filling for high value drug products.

  • Going Intensified, Connected Or Continuous?

    Hear how an adaptive and evolving platform of proven and novel technologies enables biomanufacturers to successfully accomplish their bioprocessing goals through either intensified, connected or continuous bioprocessing.

  • Using Single-Use Technology To Enable Single-Pass Tangential Flow Filtration

    As the industry is looking to increase speed to market, reduce manufacturing resources and increase product safety, there has been a push to implement single-use technologies. Combining both SPTFF and single-use technology can be a powerful tool for the efficient manufacture of biologics.

  • Cell Culture Scale-Up Using Stirred-Tank Single-Use Bioreactors

    This webinar discusses several scaling approaches, such as constant tip speed, kLa, and power number-based scale-up.

  • Culture Of 3D Cell Aggregates In Perfusion

    This webcast reviews a research example for process development with the human tumor cell line H157, cultivated in stirred-tank mini bioreactors as 3D cell aggregates.

More Enterprise Solutions Multimedia


  • Contract Manufacturing Capabilities Brochure

    With 10 state-of-the-art facilities in North America and Europe, AbbVie Contract Manufacturing offers a wide range of global contract manufacturing capabilities.

  • Contract Manufacturing Capabilities
    Contract Manufacturing Capabilities

    With 10 state-of-the-art facilities in North America and Europe, AbbVie Contract Manufacturing offers a wide range of global contract manufacturing capabilities.

  • Biologics CMO Brochure

    When you select AbbVie Contract Manufacturing for your biologics product, you’re partnering with a leading developer and manufacturer that is at the forefront of biopharmaceuticals with both our own products and customers’ products. Our scientific team and state-of-the-art facilities clearly demonstrate the capability to optimize success all the way from innovation to commercialization.

More Enterprise Solutions